Enodia Therapeutics

Founded in 2025, Enodia Therapeutics operates from its headquarters in Paris, France, developing therapies focused on immuno-inflammatory diseases.Enodia Therapeutics specializes in the development of small-molecule therapies designed for the selective degradation of disease-driving proteins, focusing on immuno-inflammatory disorders. Their approach targets the initiation of protein synthesis to eliminate pathogenic proteins before they mature and contribute to disease progression. This innovative strategy leverages the Sec61 translocon, which is crucial for the translocation of secretory and transmembrane proteins across the endoplasmic reticulum membrane. Enodia's core offerings aim to address inflammatory and autoimmune diseases, with research originating from the Institut Pasteur and development supported by Argobio. The company’s transaction structure primarily involves B2B relationships, focusing on partnerships that facilitate the advancement of its targeted protein degradation platform. Enodia’s revenue model includes milestone payments tied to the successful development stages of its products and royalties on sales once therapies reach the market. The company aims to introduce new therapies designed for specific conditions within the next two years, while also planning to expand its market reach into additional European and North American regions by 2026.

1. Seed

   Dec 9, 2025

   Amount

   $24M

   Investors

   Locked